Myriad Genetics (STU:MYD) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 26, 2026)


STU:MYD Myriad Genetics Inc STU:MYD
53 GF Score
Price €4.73
GF Value €13.18
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Myriad Genetics Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Myriad Genetics's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

STU:MYD vs PRE, FLGT, IMDX: Margin of Safety % (DCF FCF Based) Comparison

For the Diagnostics & Research subindustry, Myriad Genetics's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Myriad Genetics Margin of Safety % (DCF FCF Based) vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Myriad Genetics's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Myriad Genetics's Margin of Safety % (DCF FCF Based) falls into.


STU:MYD
53GF Score
Myriad Genetics Inc STU:MYD
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Myriad Genetics (STU:MYD) Overvalued in 2026?

Based on GuruFocus' analysis, Myriad Genetics stock appears to be undervalued. The current stock price of €4.73 is trading 64.1% below its estimated GF Value™ of €13.18. GuruFocus considers Myriad Genetics to be Possible Value Trap.

Key valuation signals for STU:MYD:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: €13.18 vs. price of €4.73 (64.1% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the STU:MYD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Myriad Genetics Business Description

Other Exchanges MYGN:USA0K3W:UKMYD:Germany
Address 322 North 2200 West, Salt Lake City, UT, USA, 84116
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
53GF Score

Get the complete analysis for STU:MYD

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.73
Price
€13.18
GF Value